Purpose To understand the potential interaction between antiarrhythmic therapy and the implantable cardioverter defibrillator (ICD) in patients who receive pharmacologic therapy as an adjunct to ICD therapy Data so...
Objective Catecholamines antagonize the clinical efficacy of pure class Ⅲ antiarrhythmic agents in vivo. The antiarrhythmic agent d, l sotalol has β adrenergic blocking properties and class Ⅲ activity. However, ...